Carsten Brunn

Dr. Carsten Brunn is Head of Pharmaceuticals at Bayer. He was appointed in January 2017 to lead Bayer’s Pharmaceuticals business in the United States, Canada, and Latin America and is an executive member of the Country Council.

Over the last 25 years, he has held a number of senior leadership positions in Europe, Asia and the United States at leading companies such as Eli Lilly, Novartis and Bausch, and Lomb. Most recently, he was Head of Bayer Pharmaceuticals Commercial Operations in Japan where he achieved double-digit growth that led to Bayer being recognized as one of the top 10 pharmaceutical companies in Japan for the first time in 26 years. He also served as the Chairman of the European Federation of Pharmaceutical Industries and Associations (EFPIA) Japan, an organization representing 24 R&D based innovative pharmaceutical companies in Japan. Dr. Brunn joined Bayer Pharmaceuticals in China in 2011 to lead the Global Primary Care business.

Dr. Brunn started his career at Eli Lilly and Company, where he held a variety of managerial positions in sales and marketing in the United States. He is passionate about meeting the needs of customers and patients and has a proven track record for building the right internal culture to drive business growth.

Dr. Brunn graduated from the University of Freiburg in Germany with a Master of Science in Pharmaceutical Science. In addition, he studied at the University of Washington under a research scholarship. He received his PhD in Chemistry from the University of Hamburg, Germany and completed his executive education at London Business School.